CytomX Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

CTMX$1.980.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share data)

Three Months Ended · Nine Months Ended
	September 30,		September 30,
	2025	2024	2025	2024
Revenues	$5,963	$33,432	$75,538	$100,010
Operating expenses:
Research and development	15,304	21,368	47,493	68,592
General and administrative	6,427	7,953	22,477	24,102
Total operating expenses	21,731	29,321	69,970	92,694
Income (loss) from operations	(15,768)	4,111	5,568	7,316
Interest income	1,592	1,693	3,725	5,858
Other (expense) income, net	5	(7)	33	(19)
Income (loss) before income taxes	(14,171)	5,797	9,326	13,155
Provision for income taxes	58	61	184	162
Net Income (Loss)	(14,229)	5,736	9,142	12,993
Other comprehensive income (loss):
Unrealized (loss) gain on investments, net of tax	71	44	77	(55)
Total comprehensive income (loss)	$(14,158)	$5,780	$9,219	$12,938
Net income (loss) per share:
Basic	$(0.09)	$0.07	$0.07	$0.15
Diluted	$(0.09)	$0.07	$0.07	$0.15
Weighted average common shares used to compute net income (loss) per share
Basic	165,004,291	85,093,227	127,352,366	84,005,093
Diluted	165,004,291	85,204,709	128,859,852	84,428,843

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.